■ PolyActiva has completed patient enrollment for its phase 1 clinical trial to study the safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma. The implant delivers latanoprost free acid to the eye for at least 30 weeks without the patient needing to administer drops, and then it biodegrades completely, leaving no residue. Compliance is a major problem globally for patients with glaucoma, with studies showing up to 46% of patients forget to use their drops or administer them poorly.